180601-53-0Relevant articles and documents
Anti-viral compounds
-
, (2008/06/13)
The present application provides a series of benzimidazole compounds of formula I: which inhibit the growth of picornaviruses, such as rhinoviruses (bovine and human), enteroviruses such as polioviruses, coxsackieviruses of the A and B groups, or echo virus, cardioviruses such as encephalomyocarditis (EMC), apthoviruses such as foot and mouth disease virus, and flaviviruses such as hepatitis C virus and bovine viral diarrhea virus. Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.
Anti-viral compounds
-
, (2008/06/13)
The present application provides a series of benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus and flaviviruses such as hepatitis C and bovine diarrheal virus.
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime
Victor, Frantz,Brown, Thomas J.,Campanale, Kristina,Heinz, Beverly A.,Shipley, Lisa A.,Su, Kenneth S.,Tang, Joseph,Vance, Lori M.,Spitzer, Wayne A.
, p. 1511 - 1518 (2007/10/03)
A series of vinylacetylene analogs of Enviroxime (1) was synthesized. The new compounds are potent inhibitors of poliovirus in tissue culture. Cross-sensitivity with Enviroxime-derived mutants shows that the new compounds have the same mechanism of action as Enviroxime, which involves the viral 3A protein. In studies with Rhesus monkeys, the p-fluoro derivative 12 was found to be unique in providing oral bioavailability. Metabolism studies using hepatic microsomes suggest that this procedure would be a useful in vitro method for selecting the appropriate animal model for testing oral absorption. Compound 12 was found to be efficacious by oral administration in treating a Coxsackie A21 infection in CD-1 mice.
